Curated News
By: NewsRamp Editorial Staff
November 03, 2026

Kairos Pharma's ENV-105 Shows 17.7-Month PFS in Prostate Cancer Trial

Discuss on Substack
Original Source

TLDR

  • Kairos Pharma's ENV-105 plus apalutamide showed 17.7-month median PFS versus two months, a statistically significant advantage for KAPA in mCRPC.
  • ENV-105 targets CD105 to reverse drug resistance, and the Phase 2 trial compares ENV-105 plus apalutamide to apalutamide alone in mCRPC patients.
  • Kairos Pharma's ENV-105 could restore sensitivity to standard therapies, potentially improving survival and quality of life for patients with resistant cancers.
  • Kairos Pharma presented interim Phase 2 data showing ENV-105 plus apalutamide extended median PFS to 17.7 months in mCRPC, versus two months with apalutamide alone.

Impact - Why it Matters

The interim Phase 2 data for ENV-105 are striking: a median progression-free survival of 17.7 months versus two months for apalutamide alone suggests a potential paradigm shift in treating metastatic castration-resistant prostate cancer. If validated in larger trials, ENV-105 could offer a new weapon against drug resistance, a major obstacle in oncology. For patients whose cancers have become resistant to standard therapies, this approach of targeting CD105 to restore sensitivity could extend lives and improve quality of life. Investors should note the statistically significant result (P=0.0008) and the planned expansion to first-line post-enzalutamide therapy, which could significantly broaden the drug's market. The news also highlights Kairos Pharma's innovative structural biology platform and its potential to address unmet needs across multiple cancer types.

Summary

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming drug resistance in cancer, announced that President and Chief Scientific Officer Neil Bhowmick is presenting interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. ENV-105, a first-in-class CD105/BMP signaling inhibitor, is being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and a Phase 2 trial in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC).

An interim analysis of the Phase 2 trial demonstrated a statistically significant improvement in median progression-free survival (PFS) among patients receiving ENV-105 plus apalutamide compared with apalutamide alone, with median PFS of 17.7 months versus two months, respectively (P=0.0008). The trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. Previous preclinical research has also demonstrated the potential of ENV-105 to enhance radiation sensitivity in prostate cancer models. Bhowmick said the findings support the company’s hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies.

To view the full press release, visit https://ibn.fm/PIrky. Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA. TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; article and editorial syndication to 5,000+ outlets; enhanced press release enhancement to ensure maximum impact; social media distribution via IBN to millions of social media followers; and a full array of tailored corporate communications solutions.

Source Statement

This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Kairos Pharma's ENV-105 Shows 17.7-Month PFS in Prostate Cancer Trial

Blockchain registration record for this content